Author's response to reviews

Title: A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure

Authors:

Simon P Ramseier Dr. (simon.ramseier@ksa.ch)
Serge Roth Dr. (serge.roth@latour.ch)
Adam Czaplinski Professor (czaplinski@gmx.ch)

Version: 2 Date: 15 July 2014

Author's response to reviews: see over
To:  

The Editor-in-chief, *BioMed Central Neurology Journal*

Subject: Revisions made as per BMC Neurology’s specifications

Dear Sir/Madam,

As suggested by the journal’s office, we have made some changes to the manuscript entitled “A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure”, that we had submitted for publication in the *BMC Neurology Journal* as a research article.

Below is a point-by-point summary of the changes made in the manuscript draft:

<table>
<thead>
<tr>
<th>Changes suggested by the BMC neurology</th>
<th>Action taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Please revise your manuscript to include line and page numbers</td>
<td>Manuscript draft revised to include line and page numbers</td>
</tr>
<tr>
<td>• For manuscripts with more than one author, all BMC Series journals require an Authors’ Contributions section to be placed after the Competing Interests section.</td>
<td>Authors’ contribution section added in the revised manuscript draft</td>
</tr>
<tr>
<td>• We are pleased to be participating in the “Resource Identification Initiative” project with the Neuroscience Information Framework - <a href="http://neuinfo.org/">http://neuinfo.org/</a>.</td>
<td>We believe this project is not applicable to the work we have submitted in our manuscript. Our work did not include any of the key resources identified in this project and was not a clinical trial.</td>
</tr>
</tbody>
</table>

We look forward to your feedback regarding this manuscript.

Thank you for your consideration

Sincerely,

Prof Adam Czaplinski  
Neurocentre Bellevue,  
Zurich  
Switzerland  
Phone: +41 44 295 3045; Fax: +41 44 295 3046